A unique collaboration spotlights the similar challenges faced by children battling cancer and NASA astronauts
Summer 2016 : Cancer Frontline
Aggressive HPV-related cancer responds to immunotherapy drug
Researchers have reported results of the first-ever Phase II clinical trial for treatment with the immunotherapy drug nivolumab on squamous cell carcinoma of the anal canal (SCCA), a rare malignancy that is on the rise.
The Phase II study was designed and led by researchers with MD Anderson’s Human Papillomavirus-Related (HPV) Cancers Moon Shot Program. MD Anderson enrolled 18 patients who volunteered to provide both pre- and post- treatment tissue samples. The study revealed encouraging correlations between immunologic biomarkers and responses to treatment.
“There have been no standardized treatment options for metastatic SCCA patients,” says Van Morris, M.D., assistant professor of Gastrointestinal Medical Oncology. “This study demonstrated responses in five of 18 patients treated at MD Anderson, and many of the patients had significant reductions in their tumor size.”
The findings were presented at the American Association for Cancer Research’s annual meeting in New Orleans.
“In this first prospective Phase II trial for refractory metastatic SCCA, our exploratory analysis of preand on-treatment tissue samples revealed potential correlations between immunologic biomarkers and clinical outcomes to nivolumab,” says Cathy Eng, M.D., professor of Gastrointestinal Medical Oncology and national study principal investigator.
Metastatic SCCA, a cancer often associated with HPV infection, is normally treated with chemotherapy, although no trials have established a standard of care.
The study employed the monoclonal antibody nivolumab, one of the drugs represented among the growing arsenal of immunotherapies. The drug frees the immune system to attack cancer by disrupting a brake that halts immune response.
“This the first formal clinical trial completed with patients with previously treated metastatic SCCA,” says Morris. “In this trial, patients received a biopsy just before being treated with nivolumab and then a second paired biopsy after two doses.”
More Stories From Conquest
Surgeon. Engineer. Astronaut.
Orthopedic oncologist Robert Satcher has always reached for the stars
Broadening the immunotherapy attack
A successful immune attack that began with melanoma is being extended to other cancers
The AGCTs of cancer
How MD Anderson researchers are working with The Cancer Genome Atlas to unravel the mysteries of the disease
Inheriting a greater risk for cancer
Genetic testing can detect many hereditary cancer syndromes, allowing for early prevention
A Healing Light
How lasers are used to attack ‘inoperable’ brain and spinal tumors
They made Jonathan Cope’s new jaw with a 3-D printer
Plastic surgery experts are using the technology to craft customized body parts that replace those damaged by cancer
On this night, they’re not patients, just teens at prom
Prom Party Palooza gave teen cancer patients the chance
to put cancer aside and just have a good time
MD Anderson is helping an at-risk group beat nicotine addiction
People with psychiatric disorders are more likely to be smokers. A new program is training community health providers to deliver tobacco cessation services.
